prospective study to assess vancomycin serum concentrations in pediatric patients with current dosing guidelines

Concerns about increasing bacterial resistance to vancomycin, have caused the adult treatment guidelines to recommend higher trough concentrations based on the type and location of infectious disease. Although these recommendations are not specific to children, the values can be extrapolated. This prospective study was designed to evaluate efficacy of current vancomycin dosing recommendations to achieve therapeutic trough serum concentration in pediatric patients. Laboratory data, vancomycin dosing and subsequent serum concentrations of children in a community teaching pediatrics hospital were collected and analyzed. Trough serum levels were determined at steady state and compared with Infectious Disease Society of America [IDSA] 2011 guidelines for the treatment of Methicillin-Resistant Staphylococcus Aureus [MRSA] infections. In a prospective observational, cross-sectional study in a university medical center in Tehran, Iran, 50 patients, who received vancomycin for more than 4 doses, were recruited and their trough vancomycin level was determined. The mean age and creatinine clearance of patients were 5.47 +/- 4.24 and 87.5 +/- 31.25, respectively. Eleven [22%] patients received vancomycin at 40 mg/kg/day [low dose] and 39 [78%] at 60 mg/kg/day [high dose]. Considering trough goals of 10-14 and 15-20mg/L in low and high dose groups, serum levels in 91% [73% sub-therapeutics] and 85% [69% sub-therapeutics] of patients were not in recommended therapeutic range, respectively. This study has shown that current recommended vancomycin dosing regimens in pediatric patients [40-60 mg/kg/day], resulted in sub-therapeutic serum concentrations in our study population

Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella [MMR] vaccination in children

In Iran, the measles, mumps and rubella vaccine [MMR] is administered in a two-dose protocol where the first dose is scheduled at 12 months of age. This study aims to determine the efficacy of the MMR vaccine by testing IgM and IgG antibody levels 4 - 7 weeks after primary vaccination. A single group cohort study was performed on healthy children, 12 - 15 months of age, who were vaccinated at health centers affiliated with Shahid Beheshti University of Medical Sciences in Tehran, from January to April 2009. Children with negative vaccination and/or clinical history for measles, mumps or rubella were administered the first dose of the MMR live attenuated vaccine. IgG and IgM antibodies were checked by enzyme linked immunoassay [ELISA] in serum samples 4 - 7 weeks after vaccination. A child was considered seropositive if antibody levels were higher than the assay cut-off level set by the ELISA kit. Samples from 240 children were checked for antibodies against measles and rubella. Measles serum IgM level was positive in 71.7% of samples and IgG in 75.8%. The rubella serum IgM level was positive in 71.7% of children and IgG in 73.8%. From 190 blood samples that were checked for mumps antibodies, serum IgM was positive in 68.9% and IgG in 95.3%. No significant relationship was found between seropositivity and age or gender. IgG and IgM antibody levels were below the assay cut-off levels against measles and rubella in approximately one-fourth of the children following primary MMR vaccination. A second dose was necessary to raise the level of protection against measles and rubella

use of polymerase chain reaction assay versus cell culture in detecting neonatal chlamydial conjunctivitis

One of the most common bacterial infections that causes ophthalmia neonatorum is Chlamydia trachomatis, [C. trachomatis]. Very few studies have been performed in Iran using both cell culture and polymerase chain reaction [PCR] methods to determine the prevalence of C. trachomatis as an etiological agent of ophthalmia neonatorum. This study aimed to evaluate the prevalence of neonatal chlamydial conjunctivitis [NCC] as diagnosed by both methods in two hospitals in Tehran, Iran. From March 2008 to May 2009, out of 2253 neonates, 241 [10.7%] with clinical findings of conjunctivitis were included in this study. A total of241 conjunctival swabs were tested by cell culture [as the gold standard test], PCR, and Giemsa staining. Cell cultures were positive for C. trachomatis in 31 [12.9%] neonates, C. trachomatis was positive in 40 [16.6%] neonates by PCR and 18 [7.5%] by Giemsa staining. The sensitivity of PCR was 100%, whereas Giemsa staining sensitivity was 58.1%. High sensitivity [100%] and specificity [95.7%] of PCR as compared to culture makes it a proper diagnostic method for the detection of C. trachomatis